ImmunityBio Investors Urged to Take Action Ahead of Class Action Deadline

In recent events, ClaimsFiler, a free service for shareholder information, has sent a crucial reminder to ImmunityBio investors. If you have suffered losses over $100,000, you are not alone and should consider taking action. The deadline to file applications to be a lead plaintiff in a class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) is set for May 26, 2026. This legal proceeding stems from allegations against the company for failing to disclose critical information between January 19, 2026, and March 24, 2026, during which the stock’s price was impacted significantly.

Background of the Lawsuit

The class action lawsuit alleges that ImmunityBio and some of its executives mismanaged investor trust by not revealing material facts concerning the company’s pharmaceutical product, Anktiva. Most notably, the legal claim invokes a warning issued by the U.S. Food and Drug Administration (FDA) on March 24, 2026. This warning, which surfaced from a letter dated March 13, indicated that a promotional video and podcast presented by ImmunityBio created misleading impressions regarding Anktiva’s efficacy. Not only did this misrepresentation lead to public health concerns, but it also caused a significant drop in the company’s stock price. Following the news release, ImmunityBio's shares plummeted by $1.98, marking a drastic 21% decrease, closing at $7.42 per share on the same day.

Why You Should Consider Filing

For those who acquired ImmunityBio shares within the defined class period, taking action could be crucial. Being recognized as a lead plaintiff can offer a potential pathway to recoup losses, as participants of the class may end up receiving settlements. Investors are reminded that the timeline for filing is limited and having sufficient information regarding their losses and the claims is vital. ClaimsFiler offers a platform where investors can register for free and access essential details concerning various securities class action lawsuits.

Getting Legal Support

Investors needing assistance are encouraged to reach out to ClaimsFiler or consult with the law firm Kahn Swick & Foti, LLC, which is ready to discuss potential legal actions and evaluate individual claims. Whether by visiting the ClaimsFiler website or contacting them through their toll-free hotline (844-367-9658), investors can gather the necessary details to make an informed decision regarding their next steps.

Conclusion

The window of opportunity to participate in this class action lawsuit is nearing its end, and those affected must act promptly. ImmunityBio’s ongoing events demonstrate the complexities of the pharmaceutical industry and the significant impacts of regulatory actions on stock performance. If you find yourself among the investors with considerable losses, remember that the stakes are high, and navigating this landscape with appropriate legal support can make a notable difference in recovering your investment. It is essential to stay informed and act quickly before the deadline passes.

For more information, visit ClaimsFiler today.